A kit for analysis of two or more of Flu A, Flu B, RSV A, and/or RSV B that may be present in a biological sample, comprising two or more of the primer pairs set forth in (a), (b), (c), (d) and (e): (a) a first Influenza A (Flu A) primer pair for generating a first Flu A amplicon if Flu A is present in the biological sample, the first Flu A primer pair comprising a first Flu A primer and a second Flu A primer, wherein: (i) the first Flu A primer that is substantially complementary to a first Flu A target nucleic acid sequence, is about 18 to about 100 contiguous bases in length and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NO: I and SEQ ID NO:23; and (ii) the second Flu A primer that is substantially complementary to a second Flu A target nucleic acid, is about 18 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:28; and (b) a second Flu A primer pair for generating a second Flu A amplicon if Flu A is present in the biological sample, the second Flu A primer pair comprising a third Flu A primer and a fourth Flu A primer, wherein: (1) the third Flu A primer that is substantially complementary to a third Flu A target nucleic acid sequence , is about 19 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS;2 to 5 and 24; and (ii) the fourth Flu A primer that is substantially complementary to a fourth Flu A target nucleic acid sequence, is about 20 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:26 & 27; and (c) an Influenza B (Flu B) primer pair for generating a Flu B amplicon if Flu B is present in the biological sample, the Flu B primer pair comprising a first Flu B primer and a second Flu B primer, wherein: (i) the first Flu B primer that is substantially complementary to a first Flu B target nucleic acid sequence, is about 22 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting SEQ ID NOS;29 & 67; and (ii) the second Flu B primer that is substantially complementary to a second Flu B target nucleic acid sequence, is about 21 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:68 to 70; and (d) a Respiratory Syncytial Virus A (RSV A) primer pair for generating an RSV A amplicon if RSV A is present in the biological sample, the RSV A primer pair comprising a first RSV A primer and a second RSV A primer, wherein: (i) the first RSV A primer that is substantially complementary to a first RSV A target nucleic acid sequence, is about 26 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:79 & 88; and (ii) the second RSV A primer that is substantially complementary to a second RSV A target nucleic acid sequence, is about 22 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:72 to 74 & 92 to 96; and (e) a Respiratory Syncytial Virus B (RSV B) primer pair for generating an RSV B amplicon if RSV B is present in the biological sample, the RSV B primer pair comprising a first RSV B primer and a second RSV B primer, wherein: (i) the first RSV B primer is substantially complementary to a first RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:99 to 101 and 106; and (ii) the second RSV B primer is substantially complementary to a second RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 104 to 106 & 115.